Ipamorelin 2mg

Description

Ipamorelin Technical Overview

Ipamorelin is a synthetic pentapeptide developed as a growth hormone secretagogue. It interacts with GHS-R1a, the receptor associated with the endogenous hormone ghrelin.

Experimental research has investigated Ipamorelin receptor pharmacology, growth hormone-related endocrine signaling, and compound selectivity compared with other secretagogues.

Ipamorelin is chemically distinct from GHRP-2 and GHRP-6.

Compound Specifications

Storage and Handling

• Use manufacturer-validated stability conditions.
• Protect from moisture, light, and contamination.
• Use appropriate laboratory peptide handling procedures.

Lyophilized Format

Ipamorelin may be supplied in lyophilized form. Physical characteristics depend on its formulation.

Research Use Disclaimer

Ipamorelin is not FDA-approved for human therapeutic use. Not intended for human or veterinary administration.

Frequently Asked Questions

What Is Ipamorelin?

A synthetic five-amino-acid growth hormone secretagogue.

What Receptor Does It Target?

GHS-R1a.

How Does It Differ From GHRP-2?

They have different peptide sequences and pharmacological profiles.

What Research Areas Involve Ipamorelin?

Ghrelin receptor signaling and endocrine regulation.

Research Overview

Ipamorelin has been investigated in research involving synthetic activation of the ghrelin receptor system.

GHS-R1a Signaling

Experiments characterize receptor activation.

Growth Hormone Research

Studies examine endocrine responses to receptor agonism.

Secretagogue Selectivity

Comparative research evaluates differences among synthetic secretagogues.

Research Applications

References

1. Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. Publication record.

Certificate of Analysis (COA)

Documentation should identify peptide sequence, purity, and content.

Peptide Lives